Biologic drugs produced only in living systems and offer revolutionary treatment for unmet clinical needs. 1 in 3 new drugs approved today – biologics; 40% of the biopharma R&D pipeline consists of biologics; biologics market worth $250B; $500B by 2025 (CAGR: 10%-11%).
When the exclusivity expires, biologics face competition from follow-on products called ‘biosimilars’. Their market is projected to reach $60B by 2025 (CAGR: 25%-30%).
The problem: Biologics, and biosimilars, are very expensive – average price in the US: $10 – $50K/year; some exceeding $500K/year. Therefore only a fraction of the patients can afford it. Manufacturing in traditional platforms is risky and costly, 1gr. of API costs $500 to $1,000.
Solution: BioBetter revolutionary, proprietary production platform using Tobacco plants in the open-field plantation as bioreactors. Our unique genetic engineering and purification process reduce the production costs by over 95% and enables vast affordability of biologic